That's a big concern as it's not approved for use anywhere in the world
10.1007/s00394-013-0511-0 29 RinninellaE.CintoniM.RaoulP.PozzoC.StrippoliA.PonzianiF
Possible mechanisms: Weight loss and reduction in visceral adiposity may relieve suppression of the HPG axis
Its an effective tool for improving muscle growth, aiding in fat loss, and supporting tissue repair
About Daiichi Sankyo Group Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs
As they promote weight loss, Semaglutide GLP-1 injections reduce the risk of complications associated with obesity, such as cardiovascular disease, high blood pressure, and high cholesterol
